AzTrials
AzTrials

Surgery-ComplicationsPOURNCT06051916

Post-operative Residual Voiding Volume Following Bulking and Vaginal Prolapse Surgery and Impact on In-hospital Stay

A study testing residual urine in people with Surgery-Complications, run by Odense University Hospital at 1 site in Denmark.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Post operative urinary retention is a commonly observed complication following women undergoing urogynecology surgery. The trial includes patients undergoing bulking and vaginal prolapse surgery, who are randomized in two postoperative groups prior to surgery in order to test two void regimes. Read more about this study

Who is it for?
Ages 18 years and older, women only
Conditions the study is for
Surgery-Complications
What is being tested?
residual urine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
84 participants
Where
1 siteDenmark
Study dates
1 Nov 2023to 1 Oct 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • • Women who undergo anterior, posterior or vaginal vault prolapse surgery or bulking surgery at the departments of obstetric and gynecology, OUH.
  • Women who have the catheter removed at the operating room.
  • Women >18 years old.

Who cannot join

  • Any surgery performed by due to malignancy
  • Previous cancer in the pelvic area
  • Previous radiation therapy in the pelvic area
  • Previous surgery in the pelvic area
  • Patients not understanding Danish
  • Patients with mental or similar illness
  • Patients with multiple sclerosis or diabetes type 1
  • Patients with late KAD removal based on per operative assessment

Trial locations and contacts

1 site in 1 country.

martin Rudnicki, professor contact

22325313

martin.rudnicki@rsyd.dk

Ulla Darling, Professor contact

66113333

Ulla.Darling.Hansen@rsyd.dk

Denmark1 site, 1 recruiting
  • martin Rudnicki

    Odense C, Odense, 4300

    ulla Darling, Consultant

    Recruiting

Other trials in Denmark

About this study

Post operative urinary retention is a commonly observed complication following women undergoing urogynecology surgery.

The trial includes patients undergoing bulking and vaginal prolapse surgery, who are randomized in two postoperative groups prior to surgery in order to test two void regimes. One group includes a strict voiding regime, where patients are discharged when voiding volume is minimum 150 ml and residual volume is maximum 200 ml. Comparatively, the minimalistic voiding group discharge patients after one spontaneous voiding, independent of voiding volume and residual volume.

The primary aim of this study is to evaluate time to discharge in two different voiding trials techniques (strict vs minimalistic) after anterior, posterior or vaginal vault prolapse surgery as well as bulking surgery. Secondly, to register the development of postoperative urinary tract infection, urine retention, gynecological pain and patients' calls to the gynecological ward after discharge.

Read the detailed description

Project description Aim The primary aim of this study is to evaluate time to discharge in two different voiding trials techniques (strict vs minimalistic) after anterior, posterior or vaginal vault prolapse surgery as well as bulking surgery.

Secondly, to evaluate the frequency of postoperative urinary tract infection, urine retention and pain as well as patients' calls to the gynecological ward after discharge.

Hypothesis The hypothesis is that the intervention group (minimalistic trial) will have an earlier discharge and fewer complications compared to the other group (strict trial).

Materials and methods The study will be performed as a two-armed parallel randomized controlled trial. Relevant patients at Odense University Hospital will be informed about the study at the preoperative consultation.

Prior to inclusion all patients are provided with verbal and written information regarding the study protocol and they give their informed consent. All patients will be randomized by a computer-generated list in a ratio of 1:1 to either strict or minimalistic regime. Randomization is done using Redcap. An independent statistician generates the random allocation sequence. The study will be blinded for the operating doctor.

Group A receives a strict voiding trial and group B receives a minimalistic voiding trial. In both groups the patient's catheter is removed at the operation room before returning to the gynecological ward.

Group A is the control group and presents the current procedures with strict voiding trial. Here, the patient will postoperatively try to void approximately every second hour after catheter removal or if she has sensation of bladder filling. The bladder is scanned before voiding to determine the bladder volume, and the voiding volume is measured. If the voiding volume is >150 ml and the residual volume is <200 ml, the patient can be discharged. If the patient cannot fulfill the criteria at the first voiding, the patient voids again 1 hour later and so on. If the residual volume is above 300 ml intermittent catheterization will be placed and the voiding trial regime restarts. If no acceptable residual volume is reached, the patient will be instructed in intermittent catheterization and there will be a postoperative follow-up the day after by telephone. If intermittent catheterization is not possible a closed catheter is placed which is opened approximately every third hour. The following day the patient will perform the voiding trial once again at the gynecological ward.

Group B is the intervention group with minimalistic voiding trial. The patients in this group need to have one spontaneous voiding before discharge with the sensation of normal voiding, meaning there is no measurement of the voiding volume or residual volume.

If the patients fail having spontaneous voiding or if the patients are in pain, the patients will undergo an ultrasound scanning to determine the bladder volume. If the patient's residual volume is above 400 ml the patient will be considered as failure and follow group A regime. If the patient's residual volume is under 400 ml the patient will continue group B regime and restart the regime.

To determine the development of postoperative urinary tract infection, urine retention and gynecological pain, the patients will have to answer a questionnaire when included in the study and two postoperative questionnaires at two weeks and three months after surgery. These questionnaires will be sent to e-box by using Open Redcap.

To assess the patients' need for guidance after surgery, the patients' calls to the gynecological ward after discharge will be registered.

Power calculation The sample size is calculated by means of medical-statistics.dk and the test 'comparing two-sample means'. Assuming the difference stated above, with a power of 80% we would need to allocate 84 patients (42 in each group) in the study. Estimating a drop-out rate of 10% we aim to include 47 in each group.

Inclusion criteria

  • Patients who undergo anterior, posterior or vaginal vault prolapse surgery or bulking surgery at the departments of obstetric and gynecology, OUH.
  • Patients who have the catheter removed at the operating room.
  • Patients >18 years old.

Exclusion criteria

  • Any surgery performed by due to malignancy
  • Previous cancer in the pelvic area
  • Previous radiation therapy in the pelvic area
  • Previous surgery in the pelvic area
  • Patients not understanding Danish
  • Patients with mental or similar illness
  • Patients with multiple sclerosis or diabetes type 1
  • Patients with late KAD removal based on per operative assessment

Statistical analysis Descriptive statistics In the study the baseline data and characteristics will be reported as means or numbers with 95% confidence intervals with a significance level set at an alpha of 0,05. Differences between groups will be evaluated by Chi square or Fisher's exact test. When appropriate, unadjusted odds ratio's with 95% confidence intervals will be calculated.

Ethical consideration The study will be approved by Fortegnelse for Forskningsprojekter, Region of Southern Denmark.

The study will be conducted according to the principles of the Declaration of Helsinki II.

Being tested
residual urine
Keywords
surgery, complication

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • residual urineOther

    The study includes two group, A and B. Se previously

Study groups in NCT06051916
Study groupRoleWhat they receive
group BActive comparatorGroup B is the intervention group with minimalistic voiding trial. The patients in this group need to have one spontaneous voiding before discharge with the sensation of normal voiding, meaning there is no measurement of the voiding volume or residual volume.
Receives: Other: residual urine
Group ANo interventionGroup A is the control group and presents the current procedures with strict voiding trial. The bladder is scanned before voiding to determine the bladder volume, and the voiding volume is measured. If the voiding volume is >150 ml and the residual volume is <200 ml, the patient can be discharged. If no acceptable residual volume is reached, the patient will be instructed in intermittent catheterization

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Residual urine

    Residual urine after surgery

    Measured: 12 hours postoperatively

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Sep 2023
  2. Study start1 Nov 2023
  3. Primary completion1 Oct 2025 (estimated)
  4. Study completion1 Oct 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Sequential
Model description
Group A receives a strict voiding trial and group B receives a minimalistic voiding trial. In both groups the patient's catheter is removed at the operation room before returning to the gynecological ward.
Masking
None (open label)
Enrolment
84 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06051916
Sponsor's protocol ID
Odense University Hospital SDU
Acronym
POUR
Status last verified
Apr 2024
First submitted
18 Sep 2023
Last updated
4 Apr 2024
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: no plan

Questions about this trial

What is this clinical trial studying?

A study testing residual urine in people with Surgery-Complications, run by Odense University Hospital at 1 site in Denmark.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 4 Apr 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact martin Rudnicki, professor (22325313, martin.rudnicki@rsyd.dk), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Residual urine (time frame: 12 hours postoperatively). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Apr 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in